pharvaris’ commitment to patients
Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disease that occurs in approximately 1 in 10,000 to 1 in 50,000 people, according to HAEi.
Pharvaris is dedicated to improving the treatment of HAE and the quality of life for patients through our innovative research, discovery, development, and manufacturing of novel therapeutics. The Pharvaris team is purposeful in its quest to advance new alternatives to injected therapies for all sub-types of HAE and other bradykinin B2-receptor-mediated indications.
Pharvaris is currently advancing its wholly-owned clinical-stage program designed to provide patient benefit in HAE.
- The RAPIDe-1 study is a clinical research study for people who have been diagnosed with hereditary angioedema (HAE).
- The main purpose of the study is to find out how effective three different doses of the study drug, PHVS416, are in relieving symptoms associated with HAE attacks.
- Researchers developed the study drug in the form of soft capsules taken by mouth, which are expected to be a more convenient alternative to an injection into a vein or under the skin for resolving HAE attacks.
Pharvaris values its relationships with patients and patient advocacy groups. We aim to make significant improvements to treatments that are available to patients with HAE. Supporting and supported by patient advocacy groups, we can help achieve this goal when patients have access to a community of peers and educational materials about their symptoms and therapeutic options.
HAE International (HAEi) is the global umbrella organization for the world’s HAE patient groups dedicated to raising awareness of HAE around the world. https://haei.org/